ArticlePakistan journal of medical sciences2025
Combined effect of Tislelizumab and chemotherapy on tumor control rate and prognosis in patients with small cell lung cancer.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical effects of the Collaborative Care Model on pulmonary function and quality of life in postoperative patients with lung cancer.Pakistan journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Exploring the effect of the combined regimen of Tislelizumab and chemotherapy on tumor control rate and prognosis in patients with small cell lung cancer (SCLC). Methods: This retrospective analysis included data of 80 SCLC patients treated in Jiangxi Cancer Hospital from April 2021 to April 2023. Forty patients who were treated with a combination of chemotherapy and Tislelizumab (the Combined group) were matched in a 1:1 ratio with a cohort receiving chemotherapy alone (the Chemotherapy group). Levels of tumor markers and T cell subsets in both groups were compared before and after treatment. After six months of follow-up, the early disease recurrence rate and survival rate of the two groups were compared. Results: The tumor control rate of the Combined group was higher than that of the Chemotherapy group ( Conclusions: Adopting the conventional combination of Tislelizumab and chemotherapy to treat SCLC can downregulate tumor marker levels, improve immune function, enhance treatment efficacy, and ensure disease prognosis. Longer follow-up is needed to confirm long-term prognostic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.